Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,497 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

NCT00660660
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
45
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

NCT00603746
View directory record Official record
Conditions
Asthma
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

NCT02278120
View directory record Official record
Conditions
Advanced Metastatic Breast Cancer
Interventions
Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
35
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead

NCT02346188
View directory record Official record
Conditions
Lead Poisoning
Interventions
Ferrous fumarate, Zinc oxide, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
6 Years to 8 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

Duloxetine vs Placebo in the Treatment of General Anxiety

NCT00475969
View directory record Official record
Conditions
Anxiety
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2007 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

NCT01263223
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 15, 2026, 1:38 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

NCT07729462
View directory record Official record
Conditions
Preventive Treatment of Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Scottsdale, Arizona • Canoga Park, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 1:38 PM EDT
Not listed Phase 1 Interventional

CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS

NCT03049046
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CC100, Placebos
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 15, 2026, 1:38 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT07497880
View directory record Official record
Conditions
Obesity, Overweight
Interventions
KAI-7535, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
31
States / cities
Chandler, Arizona • Phoenix, Arizona • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 1:38 PM EDT
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

NCT00732069
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions
Placebo, Ramipril, Valsartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT04378569
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Beverly Hills, California • Encino, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT02555683
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia

NCT00855582
View directory record Official record
Conditions
Erectile Dysfunction, Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Oct 15, 2026, 1:38 PM EDT
Not yet recruiting Phase 2 Interventional

Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism

NCT07635862
View directory record Official record
Conditions
Autism in Children, Autistic Disorder in Children and Adolescents, Autism Spectrum Disorder
Interventions
Ganaxolone (Ztalmy), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 17 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

NCT00294203
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa group, Placebo group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

NCT00676403
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
placebo, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 15, 2026, 1:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

NCT07656727
View directory record Official record
Conditions
Obesity and Cardiovascular Risk
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
16
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

NCT01081821
View directory record Official record
Conditions
Healthy
Interventions
single dose NJ-39758979/ matching placebo, multi-dose JNJ-39758979 /matching placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 15, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

NCT05047263
View directory record Official record
Conditions
Non-diabetic Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
57
States / cities
Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 15, 2026, 1:38 PM EDT